JAZZ Q2 2022 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$933M+24.1% YoY

Gross Profit

$809M86.7% margin

Operating Income

$86M9.2% margin

Net Income

$35M3.7% margin

EPS (Diluted)

$0.55

QoQ Revenue Growth

+14.6%

Cash Flow

Operating Cash Flow

$303M

Free Cash Flow

$291M

Stock-Based Comp.

$54M

Balance Sheet

Total Assets

$11.2B

Total Liabilities

$8.0B

Stockholders' Equity

$3.2B

Cash & Equivalents

$711M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$933M	$752M	+24.1%
Gross Profit	$809M	$633M	+27.8%
Operating Income	$86M	-$70M	+222.9%
Net Income	$35M	-$363M	+109.5%

Revenue Segments

Xyrem

$269M29%

Xywav

$235M26%

Epidiolex/Epidyolex

$175M19%

Rylaze/Enrylaze

$73M8%

Zepzelca

$68M7%

Defitelio/Defibrotide

$55M6%

Vyxeos

$34M4%

Sativex

$4M0%

Other Products

$2M0%

Geographic Segments

UNITED STATES

$858M92%

Europe

$61M7%

Other Countries

$14M1%